BioSpace News Archive

Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, reported financial results for the three months and full year ended December 31, 2021.

Beta Bionics, Inc. — a clinical stage medical technology company committed to the design, development, and commercialization of the iLet® Bionic Pancreas System — announced the completion of a $57 million Series C equity financing.

AVITA Medical, Inc. announced that the United States Food and Drug Administration has reviewed and approved the premarket approval application supplement for RECELL® Autologous Cell Harvesting Device, an enhanced RECELL System aimed at providing clinicians a more efficient user experience and simplified workflow.

Curis, Inc., a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced that the Company will release its fourth quarter 2021 financial results on Thursday, February 24, 2022, after the close of U.S. markets.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced financial results for the fourth quarter and full year ended December 31, 2021.

Regeneron Pharmaceuticals, Inc. will webcast management participation.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release fourth quarter and full year 2021 financial results after market close on Monday, February 28, 2022.

Ligand Pharmaceuticals Incorporated reported financial results for the three and 12 months ended December 31, 2021, and provided an operating forecast and business updates.

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the granting of patent number 6998478 titled “Powered Orthotic Device and Method of Using Same” by the Japanese Patent Office.